Search
Albiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnIt is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. … Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline).
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsNaloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca.
Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 SubstratesSynonyms: (5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diolBlinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigationala short peptide linker. … [L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery.[A254826]
Categories: Bispecific CD19-directed CD3-directed T Cell EngagerProducts: BLINCYTO® 38.5 MCG/VIAL, BLİNCYTO 38,5 MCG İNFÜZYONLUK ÇÖZELTİ İÇİN KONSANTRE TOZ VE ÇÖZELTİ, 1 ADETIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIt is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-oneAcipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalAcipimox is a niacin derivative used as a hypolipidemic agent. … Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.
Categories: Heterocyclic Compounds, 1-RingNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigationalNintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). … [A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459]
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylateTixocortol
go.drugbank.com/drugs/DB09091ApprovedWithdrawnTixocortol is a 21-thiol derivative of hydrocortisone classified as a class A corticosteroid. … It is a synthetic steroid with topical anti-inflammatory properties without the systemic glucocorticoid and mineralocorticoid activities and toxicity.[L1078]
Quinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnQuinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer. … Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia.
Categories: Heterocyclic Compounds, 2-RingSynonyms: (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamideElvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalElvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. … Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.
Mixtures: GENVOYA ® TABLETAS RECUBIERTAS, STRIBILD® TABLETAS RECUBIERTASCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InducersAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). … Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc. The annual average price of Asfotase Alfa treatment is $285,000.